medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2020-2-20-23medalphabet-1427Research ArticleСтатьиСовременные факторы риска и особенности терапии онихомикозаModern risk factors and features of treatment of onychomycosisСаканияЛ. Р.SakaniaL. R.

врач-дерматолог

г. Москва

Moscow

ПирузянА. Л.PiruzyanA. L.

д. м. н.

г. Москва

Moscow

КорсунскаяИ. М.KorsunskayaI. M.

д. м. н., проф.

г. Москва

Moscow

ГБУЗ г. Москвы «Московский научно-практический центр дерматовенерологии и косметологии» Департамента здравоохранения г. МосквыРоссияMoscow Scientific and Practical Centre for Dermatovenereology and CosmetologyRussian FederationФГБУН «Центр теоретических проблем физико-химической фармакологии» Российской академии наукРоссияCentre for Theoretical Problems of Physicochemical PharmacologyRussian Federation20201206202002Современная поликлиника2023Copyright © Сакания Л.Р., Пирузян А.Л., Корсунская И.М., 20202020Сакания Л.Р., Пирузян А.Л., Корсунская И.М.Sakania L.R., Piruzyan A.L., Korsunskaya I.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/1427

Онихомикоз является широко распространенным заболеванием ногтей, вызванным дерматофитами, дрожжами и недерматофитами. Факторами риска развития онихомикоза могут выступать различные соматические состояния, к примеру диабет, возраст, особенности образа жизни. Часто онихомикоз встречается у спортсменов. Так, по некоторым данным, у 60,7 % футболистов наблюдается данное заболевание. Причиной повышенного риска развития онихомикозов у спортсменов является ношение неподходящей обуви, частое использование синтетической одежды и обуви, сохраняющей пот, травмы ногтевых пластин. Предпочтение стоит отдавать системной терапии. Лечение может занимать до 18 месяцев, что обусловлено медленным отрастанием здоровой ногтевой пластинки. Из системных препаратов широко применяется итраконазол. Препарат может назначаться по схеме пульс‑терапии, и положительная динамика наблюдается уже через 2 месяца применения.

Onychomycosis is a widespread nail disease caused by dermatophytes, yeast and non‑dermatophytes. Risk factors for the development of onychomycosis can be various somatic conditions, for example diabetes, age, lifestyle features. Often onychomycosis occurs in athletes. According to some reports, 60.7 % of football players have this disease. The reason for the increased risk of developing onychomycosis in athletes is wearing unsuitable shoes, the frequent use of synthetic clothing and sweat‑preserving shoes, and injuries to the nail plates. Preference should be given to systemic therapy. Treatment can take up to 18 months, due to the slow regrowth of a healthy nail plate. Of the systemic drugs, itraconazole is widely used. The drug can be prescribed according to the scheme of pulse therapy, and positive dynamics is observed after 2 months of use.

онихомикозфакторы рискасистемная терапияитраконазолonychomycosisrisk factorssystemic therapyitraconazoleReferencesSmith E. B. History of antifungals. J. Am. Acad. Dermatol. 1990; 23: 776–778. DOI: 10.1016/0190–9622(90)70286-Q.Smith E. B. History of antifungals. J. Am. Acad. Dermatol. 1990; 23: 776–778. DOI: 10.1016/0190–9622(90)70286-Q.Neumann H. A. Oral treatment of onychomycosis of the toe nails; comparison of cost effectiveness of griseofulvin, itraconazole, ketoconazole and terbinafine. Ned. Tijdschr. Geneeskd. 1995; 139: 1350–1351.Neumann H. A. Oral treatment of onychomycosis of the toe nails; comparison of cost effectiveness of griseofulvin, itraconazole, ketoconazole and terbinafine. Ned. Tijdschr. Geneeskd. 1995; 139: 1350–1351.Purim K. S., Bordignon G. P., Queiroz-Telles F. Fungal infection of the feet in soccer players and non-athlete individuals. Rev. Iberoam. Micol. 2005; 22: 34–38. DOI: 10.1016/S1130–1406(05)70004–8.Purim K. S., Bordignon G. P., Queiroz-Telles F. Fungal infection of the feet in soccer players and non-athlete individuals. Rev. Iberoam. Micol. 2005; 22: 34–38. DOI: 10.1016/S1130–1406(05)70004–8.Purim K. S., de Freitas C. F., Leite N. Feet dermatophytosis in soccer player. An. Braz. Dermatol. 2009; 84: 550–552. DOI: 10.1590/S0365–05962009000500020.Purim K. S., de Freitas C. F., Leite N. Feet dermatophytosis in soccer player. An. Braz. Dermatol. 2009; 84: 550–552. DOI: 10.1590/S0365–05962009000500020.Gupta A. K., Versteeg S. G., Shear N. H. Onychomycosis in the 21st Century: An Update on Diagnosis, Epidemiology, and Treatment. J. Cutan. Med. Surg. 2017; 21: 525–539. DOI: 10.1177/1203475417716362.Gupta A. K., Versteeg S. G., Shear N. H. Onychomycosis in the 21st Century: An Update on Diagnosis, Epidemiology, and Treatment. J. Cutan. Med. Surg. 2017; 21: 525–539. DOI: 10.1177/1203475417716362.Ha S. J., Han K. D., Song Y., Lee J. H. Weight change and risk of onychomycosis: A nationwide cohort study in Korea. J. Am. Acad. Dermatol. 2018; 78: 613–614. DOI: 10.1016/j.jaad.2017.09.030.Ha S. J., Han K. D., Song Y., Lee J. H. Weight change and risk of onychomycosis: A nationwide cohort study in Korea. J. Am. Acad. Dermatol. 2018; 78: 613–614. DOI: 10.1016/j.jaad.2017.09.030.Gupta A. K., Daigle D., Foley K. A. Network Meta-Analysis of Onychomycosis Treatments. Skin Appendage Disord. 2015; 1: 74–81. DOI: 10.1159/000433473.Gupta A. K., Daigle D., Foley K. A. Network Meta-Analysis of Onychomycosis Treatments. Skin Appendage Disord. 2015; 1: 74–81. DOI: 10.1159/000433473.Garcia-Romero M.T., Granados J., Vega-Memije M.E., Arenas R. Analysis of genetic polymorphism of the HLA-B and HLA-DR loci in patients with dermatophytic onychomycosis and in their first-degree relatives. Actas Dermosifiliogr. 2012; 103: 59–62. DOI: 10.1016/j.adengl.2011.03.017.Garcia-Romero M.T., Granados J., Vega-Memije M.E., Arenas R. Analysis of genetic polymorphism of the HLA-B and HLA-DR loci in patients with dermatophytic onychomycosis and in their first-degree relatives. Actas Dermosifiliogr. 2012; 103: 59–62. DOI: 10.1016/j.adengl.2011.03.017.Carrillo-Meléndrez H., Ortega-Hernández E., Granados J., Arroyo S., Barquera R., Arenas R. Role of HLA-DR Alleles to Increase Genetic Susceptibility to Onychomycosis in Nail Psoriasis. Skin Appendage Disord. 2016; 2: 22–25. DOI: 10.1159/000446444.Carrillo-Meléndrez H., Ortega-Hernández E., Granados J., Arroyo S., Barquera R., Arenas R. Role of HLA-DR Alleles to Increase Genetic Susceptibility to Onychomycosis in Nail Psoriasis. Skin Appendage Disord. 2016; 2: 22–25. DOI: 10.1159/000446444.Abdel-Rahman S. M. Genetic Predictors of Susceptibility to Dermatophytoses. Mycopathologia. 2017; 182: 67–76. DOI: 10.1007/s11046–016–0046-z.Abdel-Rahman S. M. Genetic Predictors of Susceptibility to Dermatophytoses. Mycopathologia. 2017; 182: 67–76. DOI: 10.1007/s11046–016–0046-z.Gupta A. K., Carviel J., Shear N. H. Onychomycosis and Chronic Fungal Disease: Exploiting a Commensal Disguise to Stage a Covert Invasion. J. Cutan. Med. Surg. 2018; 22: 318–322. DOI: 10.1177/1203475417745827.Gupta A. K., Carviel J., Shear N. H. Onychomycosis and Chronic Fungal Disease: Exploiting a Commensal Disguise to Stage a Covert Invasion. J. Cutan. Med. Surg. 2018; 22: 318–322. DOI: 10.1177/1203475417745827.Zaias N., Rebell G., Casal G., Appel J. The asymmetric gait toenail unit sign. Skinmed. 2012; 10: 213–217.Zaias N., Rebell G., Casal G., Appel J. The asymmetric gait toenail unit sign. Skinmed. 2012; 10: 213–217.Zaias N., Rebell G., Escovar S. Asymmetric gait nail unit syndrome: The most common worldwide toenail abnormality and onychomycosis. Skinmed. 2014; 12: 217–223.Zaias N., Rebell G., Escovar S. Asymmetric gait nail unit syndrome: The most common worldwide toenail abnormality and onychomycosis. Skinmed. 2014; 12: 217–223.Ghannoum M., Salem I., Christensen L. Epidemiology of onychomycosis. In: Rigopoulos D., Elewski B., Richert B., editors. Onychomycosis. John Wiley & Sons; Hoboken, NJ, USA: 2018.Ghannoum M., Salem I., Christensen L. Epidemiology of onychomycosis. In: Rigopoulos D., Elewski B., Richert B., editors. Onychomycosis. John Wiley & Sons; Hoboken, NJ, USA: 2018.Lee W. J., Kim S. L., Jang Y. H., Lee S. J., Kim D. W., Bang Y. J., Jun J. B. Increasing prevalence of trichophyton rubrum identified through an analysis of 115,846 cases over the last 37 years. J. Korean Med. Sci. 2015; 30: 639–643. DOI: 10.3346/jkms.2015.30.5.639.Lee W. J., Kim S. L., Jang Y. H., Lee S. J., Kim D. W., Bang Y. J., Jun J. B. Increasing prevalence of trichophyton rubrum identified through an analysis of 115,846 cases over the last 37 years. J. Korean Med. Sci. 2015; 30: 639–643. DOI: 10.3346/jkms.2015.30.5.639.Piérard G. E. Spores, sporodochia and fomites in onychomycosis. Dermatology. 2006; 213: 169–172. DOI: 10.1159/000093862.Piérard G. E. Spores, sporodochia and fomites in onychomycosis. Dermatology. 2006; 213: 169–172. DOI: 10.1159/000093862.Eba M., Njunda A. L., Mouliom R. N., Kwenti E. T., Fuh A. N., Nchanji G. T., Atashili J. Onychomycosis in diabetic patients in fako division of cameroon: Prevalence, causative agents, associated factors and antifungal sensitivity patterns. BMC Res. Notes. 2016; 9: 494. DOI: 10.1186/s13104–016–2302–1.Eba M., Njunda A. L., Mouliom R. N., Kwenti E. T., Fuh A. N., Nchanji G. T., Atashili J. Onychomycosis in diabetic patients in fako division of cameroon: Prevalence, causative agents, associated factors and antifungal sensitivity patterns. BMC Res. Notes. 2016; 9: 494. DOI: 10.1186/s13104–016–2302–1.Vlahovic T. C. Onychomycosis: Evaluation, Treatment Options, Managing Recurrence, and Patient Outcomes. Clin. Podiatr. Med. Surg. 2016; 33: 305–318. DOI: 10.1016/j.cpm.2016.02.001.Vlahovic T. C. Onychomycosis: Evaluation, Treatment Options, Managing Recurrence, and Patient Outcomes. Clin. Podiatr. Med. Surg. 2016; 33: 305–318. DOI: 10.1016/j.cpm.2016.02.001.Lipner S. R., Scher R. K. Part I: Onychomycosis: Clinical Overview and Diagnosis. J. Am. Acad. Dermatol. 2019 DOI: 10.1016/j.jaad.2018.03.062.Lipner S. R., Scher R. K. Part I: Onychomycosis: Clinical Overview and Diagnosis. J. Am. Acad. Dermatol. 2019 DOI: 10.1016/j.jaad.2018.03.062.Jain S., Sehgal V. N. Onychomycosis: An epidemio-etiologic perspective. International Journal of Dermatology. 2000; 39 (2): 100–103. DOI: 10.1046/j.1365–4362.2000.00808.x.Jain S., Sehgal V. N. Onychomycosis: An epidemio-etiologic perspective. International Journal of Dermatology. 2000; 39 (2): 100–103. DOI: 10.1046/j.1365–4362.2000.00808.x.Grover S. Clinico-mycological evaluation of onychomycosis at Bangalore and Jorhat. Indian Journal of Dermatology, Venereology and Leprology. 2003; 69 (4): 284–286.Grover S. Clinico-mycological evaluation of onychomycosis at Bangalore and Jorhat. Indian Journal of Dermatology, Venereology and Leprology. 2003; 69 (4): 284–286.Thomas J., Jacobson G. A., Narkowicz C. K., Peterson G. M., Burnet H., Sharpe C. Toenail onychomycosis: An important global disease burden. J. Clin. Pharm. Ther. 2010; 35: 497–519. DOI: 10.1111/j.1365–2710.2009.01107.xThomas J., Jacobson G. A., Narkowicz C. K., Peterson G. M., Burnet H., Sharpe C. Toenail onychomycosis: An important global disease burden. J. Clin. Pharm. Ther. 2010; 35: 497–519. DOI: 10.1111/j.1365–2710.2009.01107.xGupta A. K., Simpson F. C., Brintnell W. C. Do genetic mutations and genotypes contribute to onychomycosis? Dermatology. 2014; 228: 207–210. DOI: 10.1159/000358586.Gupta A. K., Simpson F. C., Brintnell W. C. Do genetic mutations and genotypes contribute to onychomycosis? Dermatology. 2014; 228: 207–210. DOI: 10.1159/000358586.Buder V, Augustin M, Schäfer I, Welsch G, Catala-Lehnen P, Herberger K Prevalence of dermatomycoses in professional football players: A study based on data of German Bundesliga fitness check-ups (2013–2015) compared to data of the general population Hautarzt. 2018 May; 69(5): 401–407. DOI: 10.1007/s00105–017–4120–3.Buder V, Augustin M, Schäfer I, Welsch G, Catala-Lehnen P, Herberger K Prevalence of dermatomycoses in professional football players: A study based on data of German Bundesliga fitness check-ups (2013–2015) compared to data of the general population Hautarzt. 2018 May; 69(5): 401–407. DOI: 10.1007/s00105–017–4120–3.Peres N. T., Maranhão F. C., Rossi A., Martinez-Rossi N. M. Dermatophytes- Host-pathogen interaction and antifungal resistance. An. Braz. Dermatol. 2010; 85: 657–667. DOI: 10.1590/S0365–05962010000500009.Peres N. T., Maranhão F. C., Rossi A., Martinez-Rossi N. M. Dermatophytes- Host-pathogen interaction and antifungal resistance. An. Braz. Dermatol. 2010; 85: 657–667. DOI: 10.1590/S0365–05962010000500009.Gupta A. K., Foley K. A., Mays R. R., Shear N. H., Piguet V. Monotherapy for toenail onychomycosis: A systematic review and network meta-analysis. Br. J. Dermatol. 2019. DOI: 10.1111/bjd.18155.Gupta A. K., Foley K. A., Mays R. R., Shear N. H., Piguet V. Monotherapy for toenail onychomycosis: A systematic review and network meta-analysis. Br. J. Dermatol. 2019. DOI: 10.1111/bjd.18155.Gupchup GV, Zatz JL: Structural characteristics and permeability properties of the human nail: A review. J Cosmet Sci. 1999; 50 (6): 363–385.Gupchup GV, Zatz JL: Structural characteristics and permeability properties of the human nail: A review. J Cosmet Sci. 1999; 50 (6): 363–385.Lipner SR, Scher RK: Onychomycosis: Treatment and prevention of recurrence. J Am Acad Dermatol. 2019; 80 (4): 853–67. DOI: 10.1016/j.jaad.2018.05.1260.Lipner SR, Scher RK: Onychomycosis: Treatment and prevention of recurrence. J Am Acad Dermatol. 2019; 80 (4): 853–67. DOI: 10.1016/j.jaad.2018.05.1260.Gupta AK, Simpson FC. New pharmacotherapy for the treatment of onychomycosis: an update. Expert Opin Pharmacother. 2015; 16 (2): 227–36. DOI: 10.1517/14656566.2015.993380Gupta AK, Simpson FC. New pharmacotherapy for the treatment of onychomycosis: an update. Expert Opin Pharmacother. 2015; 16 (2): 227–36. DOI: 10.1517/14656566.2015.993380Reiss E., Shadomy H. J., Lyon G. M. Fundamental Medical Mycology. Wiley-Blackwell; Hoboken, NJ, USA: 2011. pp. 75–105.Reiss E., Shadomy H. J., Lyon G. M. Fundamental Medical Mycology. Wiley-Blackwell; Hoboken, NJ, USA: 2011. pp. 75–105.Yamada T., Maeda M., Alshahni M. M., Tanaka R., Yaguchi T., Bontems O., Salamin K., Fratti M., Monod M. Terbinafine resistance of Trichophyton clinical isolates caused by specific point mutations in the squalene epoxidase gene. Antimicrob. Agents Chemother. 2017; 61: e00115–17. DOI: 10.1128/AAC.00115–17.Yamada T., Maeda M., Alshahni M. M., Tanaka R., Yaguchi T., Bontems O., Salamin K., Fratti M., Monod M. Terbinafine resistance of Trichophyton clinical isolates caused by specific point mutations in the squalene epoxidase gene. Antimicrob. Agents Chemother. 2017; 61: e00115–17. DOI: 10.1128/AAC.00115–17.Schøsler L., Andersen L. K., Arendrup M. C., Sommerlund M. Recurrent terbinafine resistant Trichophyton rubrum infection in a child with congenital ichthyosis. Pediatr. Dermatol. 2018; 35: 259–260. DOI: 10.1111/pde.13411.Schøsler L., Andersen L. K., Arendrup M. C., Sommerlund M. Recurrent terbinafine resistant Trichophyton rubrum infection in a child with congenital ichthyosis. Pediatr. Dermatol. 2018; 35: 259–260. DOI: 10.1111/pde.13411.Digby S. S., Hald M., Arendrup M. C., Hjort S. V., Kofoed K. Darier disease complicated by terbinafine-resistant Trichophyton rubrum: A case report. Acta Derm. Venereol. 2017; 97: 139–140. DOI: 10.2340/00015555–2455.Digby S. S., Hald M., Arendrup M. C., Hjort S. V., Kofoed K. Darier disease complicated by terbinafine-resistant Trichophyton rubrum: A case report. Acta Derm. Venereol. 2017; 97: 139–140. DOI: 10.2340/00015555–2455.Singh A., Masih A., Khurana A., Singh P. K., Gupta M., Hagen F., Meis J. F., Chowdhary A. High terbinafine resistance in Trichophyton interdigitale isolates in Delhi; India harbouring mutations in the squalene epoxidase gene. Mycoses. 2018; 61: 477–484. DOI: 10.1111/myc.12772.Singh A., Masih A., Khurana A., Singh P. K., Gupta M., Hagen F., Meis J. F., Chowdhary A. High terbinafine resistance in Trichophyton interdigitale isolates in Delhi; India harbouring mutations in the squalene epoxidase gene. Mycoses. 2018; 61: 477–484. DOI: 10.1111/myc.12772.Osborne C. S., Leitner I., Favre B., Ryder N. S. Amino acid substitution in Trichophyton rubrum squalene epoxidase associated with resistance to terbinafine. Antimicrob. Agents Chemother. 2005; 49: 2840–2844. DOI: 10.1128/AAC.49.7.2840–2844.2005.Osborne C. S., Leitner I., Favre B., Ryder N. S. Amino acid substitution in Trichophyton rubrum squalene epoxidase associated with resistance to terbinafine. Antimicrob. Agents Chemother. 2005; 49: 2840–2844. DOI: 10.1128/AAC.49.7.2840–2844.2005.Osborne C. S., Leitner I., Hofbauer B., Fielding C. A., Favre B., Ryder N. S. Biological, biochemical, and molecular characterization of a new clinical Trichophyton rubrum isolate resistant to terbinafine. Antimicrob. Agents Chemother. 2006; 50: 2234–2236. DOI: 10.1128/AAC.01600–05.Osborne C. S., Leitner I., Hofbauer B., Fielding C. A., Favre B., Ryder N. S. Biological, biochemical, and molecular characterization of a new clinical Trichophyton rubrum isolate resistant to terbinafine. Antimicrob. Agents Chemother. 2006; 50: 2234–2236. DOI: 10.1128/AAC.01600–05.Gupta A. K., Daigle D., Carviel J. L. The role of biofilms in onychomycosis. J. Am. Acad. Dermatol. 2016; 74: 1241–1246. DOI: 10.1016/j.jaad.2016.01.008.Gupta A. K., Daigle D., Carviel J. L. The role of biofilms in onychomycosis. J. Am. Acad. Dermatol. 2016; 74: 1241–1246. DOI: 10.1016/j.jaad.2016.01.008.Scher R. K., Baran R. Onychomycosis in clinical practice: Factors contributing to recurrence. Br. J. Dermatol. 2003; 149: 5–9. DOI: 10.1046/j.1365–2133.149.s65.5.x.Scher R. K., Baran R. Onychomycosis in clinical practice: Factors contributing to recurrence. Br. J. Dermatol. 2003; 149: 5–9. DOI: 10.1046/j.1365–2133.149.s65.5.x.Инструкция по применения препарата Орунгамин (итраконазол).Инструкция по применения препарата Орунгамин (итраконазол).

The authors declare that there are no conflicts of interest present.